ADCT-701 / ADC Therapeutics - LARVOL DELTA

A first-in-human phase I trial with antibody drug conjugate ADCT-701 in neuroendocrine tumors and carcinomas. (ASCO-GI 2025) - P1 | "The trial aims to enroll up to 70 evaluable patients across a maximum of 10 dose levels. For further details, please refer to clinical trial information NCT06041516."

P1 data • Gastrointestinal Cancer • Oncology • Solid Tumor • DLK1

Identification of DLK1 As a Novel Therapeutic Target in Down Syndrome Myeloid Leukemia (ASH 2024) - "We used DLK1-targeting antibody drug conjugate (ADCT-701, referred to as DLK1-ADC) with a DNA intercalating agent pyrrolbenzodiazepine...Finally, DLK1-ADC, but not Iso-ADC cured 2 of 3 mice injected with a refractory ML-DS PDX model while the third mouse showed an 84-day prolongation of survival compared to that of mice treated with Iso-ADC. Thus, taken together, we have identified DLK1 as a novel therapeutic target for refractory ML-DS and show that targeting DLK1 may be a novel treatment option for patients with refractory ML-DS."

Developmental Disorders • Genetic Disorders • Hematological Malignancies • Leukemia • Oncology • CD34 • DLK1 • GATA1

A proteogenomic surfaceome study identifies DLK1 as an immunotherapeutic target in neuroblastoma. (PubMed, Cancer Cell) - "ADCT-701, a DLK1-targeting antibody-drug conjugate (ADC), shows potent and specific cytotoxicity in DLK1-expressing neuroblastoma xenograft models. Since high DLK1 expression is found in several adult and pediatric cancers, our study demonstrates the utility of a proteogenomic approach and credentials DLK1 as an immunotherapeutic target."

IO biomarker • Journal • CNS Tumor • Neuroblastoma • Oncology • Pediatrics • Solid Tumor • DLK1

Identification of DLK1, a Notch ligand, as an immunotherapeutic target and regulator of tumor cell plasticity and chemoresistance in adrenocortical carcinoma. (PubMed, bioRxiv) - P1 | "In ACC, ADCT-701, a DLK1 targeting antibody-drug conjugate (ADC), shows potent in vitro activity among established cell lines and a new cohort of patient-derived organoids as well as robust in vivo anti-tumor responses in cell line-derived and patient-derived xenografts...This works identifies DLK1 as a novel immunotherapeutic target that regulates tumor cell plasticity and chemoresistance in ACC. Our data support targeting DLK1 with an ADC in ACC and neuroendocrine neoplasms in an active first-in-human phase I clinical trial ( NCT06041516 )."

IO biomarker • Journal • Tumor cell • Adrenal Cortex Carcinoma • Endocrine Cancer • Genito-urinary Cancer • Lung Cancer • Neuroendocrine Tumor • Oncology • Small Cell Lung Cancer • Solid Tumor • ABCB1 • NOTCH1

Chiome Biosciences Announces Initiation of Administration in Phase 1 Clinical Trial of Cancer Therapy Antibody ADCT-701 [Google translation] (Nikkei) - "We are pleased to announce that ADCT-701, an antibody-drug conjugate (ADC) that combines a drug with LIV-1205, a cancer therapeutic antibody developed by our company, has been administered to the first subject (FPI: First Patient In) in a Phase 1 clinical trial conducted by the National Cancer Institute (NCI) of the National Institutes of Health (NIH)."

Trial status • Neuroendocrine Tumor • Oncology • Solid Tumor

Targeting DLK1, a Notch ligand, with an antibody-drug conjugate in adrenocortical carcinoma (AACR 2024) - P1 | "First-line therapy (adrenolytic agent mitotane in combination with chemotherapy) for recurrent and metastatic ACC has limited efficacy and there are no approved second-line therapies. In vivo studies showed that ADCT-701 was highly effective against DLK1-positive ACC xenografts and PDX models with durable anti-tumor activity. Our pre-clinical data demonstrate DLK1 as an important therapeutic target in ACC and support an upcoming phase I clinical trial of ADCT-701 in patients with neuroendocrine tumors including ACC (NCT06041516)."

IO biomarker • Adrenal Cortex Carcinoma • Endocrine Cancer • Genito-urinary Cancer • Neuroendocrine Tumor • Oncology • Solid Tumor • ANXA5 • CASP3 • DLK1 • DLL3 • JAG1

Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas (clinicaltrials.gov) - P1 | N=70 | Recruiting | Sponsor: National Cancer Institute (NCI) | Not yet recruiting ➔ Recruiting | Trial completion date: Oct 2028 ➔ Oct 2029 | Trial primary completion date: Oct 2026 ➔ Oct 2027

Enrollment open • Trial completion date • Trial primary completion date • Adrenal Cortex Carcinoma • Endocrine Cancer • Genito-urinary Cancer • Neuroendocrine Tumor • Oncology • Solid Tumor • CD4

ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire) - "ADC Therapeutics SA...today announced abstracts on its novel antibody drug conjugates (ADCs) have been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting, which will be held in San Diego, CA from April 5-10, 2024....'We’re excited to share compelling preclinical data supporting the future clinical development of the next-generation ADCs in our solid tumor portfolio, including those targeting Claudin-6 and NaPi2b, at the AACR Annual Meeting'...'We’re also looking forward to research from independent studies that highlight the potential of another investigational ADC, ADCT-601 targeting AXL.'"

Clinical data • P1 data • Preclinical • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Non-Hodgkin’s Lymphoma • Oncology • Soft Tissue Sarcoma • Solid Tumor

Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas (clinicaltrials.gov) - P1 | N=70 | Not yet recruiting | Sponsor: National Cancer Institute (NCI)

New P1 trial • Adrenal Cortex Carcinoma • Endocrine Cancer • Genito-urinary Cancer • Neuroendocrine Tumor • Oncology • Solid Tumor • CD4

ADC Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates (Businesswire) - "Upcoming Expected Milestones....ADCT-212 (targeting PSMA): Initiate Phase 1 study in 1H 2024. ADCT-602 (targeting CD22): Complete Phase 1 dose expansion study in 1H 2024. ADCT-701 (targeting DLK-1): Initiate Phase 1 study in 2H 2023."

New P1 trial • Trial status • Oncology

ADC Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates (Businesswire) - "ZYNLONTA® (loncastuximab tesirine-lpyl) net sales of $21.3 million in the third quarter of 2022 (+23% vs. 2Q 2022)...ADCT-212 (targeting PSMA)- Progress toward IND filing and initiation of Phase 1 trial in 2023; ADCT-701 (targeting DLK-1)- Progress toward IND filing and initiation of Phase 1 trial in 2023."

IND • Sales • Hematological Malignancies • Oncology • Solid Tumor

ADC Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates (Businesswire) - "Upcoming Expected Milestones: ZYNLONTA...Initiate the LOTIS-9 trial of ZYNLONTA + rituximab in 1L unfit/frail DLBCL patients in 2H 2022; Initiate the LOTIS-7 trial of ZYNLONTA in multiple combinations in NHL in 1H 2022; Cami: Report topline results for the Phase 2 trial in HL in 1H 2022; Meet with FDA for pre-BLA meeting in 2H 2022; ADCT-601 (targeting AXL): Initiate the Phase 1b combination study in multiple solid tumors in 1H 2022; ADCT-701 (targeting DLK1): Continue to work with the NCI for completion of preclinical studies to support an IND filing; ADCT-212 (targeting PSMA): Continue completion of preclinical studies to support an IND filing."

IND • New P1 trial • New trial • Preclinical • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Solid Tumor

ADC Therapeutics Highlights its Proprietary ADC Platform and Solid Tumor Pipeline (Businesswire) - "During the webcast, Chris Martin, PhD, Chief Executive Officer, Patrick van Berkel, PhD, Senior Vice President of Research & Development, and Joseph Camardo, MD, Chief Medical Officer, will discuss the broad applicability and flexibility of the Company’s novel ADC technology and provide a deep dive on its portfolio of solid tumor programs including three clinical-stage assets (Cami, ADCT-901, and ADCT-601); ADCT-701, which is approaching the clinic; and a newly disclosed program, ADCT-212, an ADC targeting PSMA with potential utility in metastatic castrate-resistant prostate cancer (mCRPC)."

Clinical • Genito-urinary Cancer • Hematological Malignancies • Oncology • Prostate Cancer • Solid Tumor

ADC Therapeutics Reports Second Quarter 2020 Financial Results and Provides Recent Business Highlights (Businesswire) - "Anticipated Upcoming Milestones: File a BLA with the FDA for Lonca for the treatment of relapsed or refractory DLBCL in the second half of 2020. Present data from the Phase 1b trial of Cami in selected advanced solid tumors at a scientific meeting in the second half of 2020. Initiate a pivotal Phase 2 trial of Lonca in follicular lymphoma (FL) in the first half of 2021. Report interim results from the pivotal Phase 2 trial of Cami in HL in the first half of 2021. Continue to accelerate the Company’s pipeline of ADC product candidates for the treatment of hematological cancers and solid tumors, including presenting Phase 1 data for ADCT-602 in acute lymphoblastic leukemia and ADCT-601 in solid tumors. Continue to advance our earlier-stage programs, ADCT-901 and ADCT-701, with IND-enabling studies."

BLA • IND • New P2 trial • P1 data • P2 data • Acute Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Solid Tumor

A multi-omic surfaceome study identifies DLK1 as an epigenetically regulated protein and immunotherapeutic target in neuroblastoma (AACR-NCI-EORTC 2019) - "DLK1 is an epigenetically regulated immunotherapeutic target in neuroblastoma. ADCT-701 shows potent activity in preclinical models of NB and should be prioritized for clinical development."

IO Biomarker • Late-breaking abstract